Bruno O. Villoutreix mostly deals with Drug discovery, Biochemistry, Bioinformatics, In silico and Virtual screening. The study incorporates disciplines such as The Internet, Information retrieval, Small molecule and Protein–protein interaction in addition to Drug discovery. Biochemistry is closely attributed to Factor V in his research.
The concepts of his Bioinformatics study are interwoven with issues in Web server, Adme tox and Lipocalin. His In silico research is multidisciplinary, incorporating perspectives in Chemical biology, Quantitative structure–activity relationship, Simplified molecular-input line-entry system, Cheminformatics and Computational biology. His study in the fields of Protein–ligand docking under the domain of Virtual screening overlaps with other disciplines such as Structure based.
His scientific interests lie mostly in Biochemistry, Binding site, Drug discovery, Computational biology and In silico. His Biochemistry research incorporates elements of Molecular biology and Thrombin. His Binding site research includes elements of Binding protein, C4b-binding protein, Complement control protein, Stereochemistry and Protein structure.
His biological study spans a wide range of topics, including Virtual screening, Nanotechnology, Web server, Small molecule and Drug. His Computational biology study also includes fields such as
His primary areas of investigation include In silico, Computational biology, Virtual screening, Drug repositioning and Drug discovery. His In silico research also works with subjects such as
His studies in Virtual screening integrate themes in fields like Active site, Field and Cheminformatics. His work deals with themes such as Chemical biology, Web server and Rational design, which intersect with Drug discovery. His Protein C study introduces a deeper knowledge of Biochemistry.
Bruno O. Villoutreix focuses on Bioinformatics, Computational biology, Chemical biology, Drug discovery and Receptor. In his work, PubChem, Chemical space, chEMBL and Online database is strongly intertwined with Identification, which is a subfield of Bioinformatics. His Computational biology research is multidisciplinary, incorporating elements of Serine protease, Protease, UniProt and Table.
His Chemical biology study necessitates a more in-depth grasp of Biochemistry. His studies examine the connections between Drug discovery and genetics, as well as such issues in Drug development, with regards to Web server. Bruno O. Villoutreix has researched In silico in several fields, including Information retrieval, Allosteric regulation and Protein–protein interaction.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Regulation of Blood Coagulation by the Protein C Anticoagulant Pathway: Novel Insights Into Structure-Function Relationships and Molecular Recognition
Björn Dahlbäck;Bruno O Villoutreix.
Arteriosclerosis, Thrombosis, and Vascular Biology (2005)
The anticoagulant protein C pathway
Björn Dahlbäck;Bruno O Villoutreix.
FEBS Letters (2005)
Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery
Stéphanie Pérot;Olivier Sperandio;Maria A. Miteva;Anne-Claude Camproux.
Drug Discovery Today (2010)
FAF-Drugs3: a web server for compound property calculation and chemical library design
David Lagorce;Olivier Sperandio;Jonathan B. Baell;Maria A. Miteva.
Nucleic Acids Research (2015)
FAF-Drugs2: Free ADME/tox filtering tool to assist drug discovery and chemical biology projects
David Lagorce;Olivier Sperandio;Hervé Galons;Maria A Miteva.
BMC Bioinformatics (2008)
Complement inhibitor C4b-binding protein: friend or foe in the innate immune system?
Anna M. Blom;Bruno O. Villoutreix;Björn Dahlbäck.
Molecular Immunology (2004)
3-Dimensional structure of membrane-bound coagulation factor VIII: Modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography
Svetla Stoilova-McPhie;Bruno O. Villoutreix;Koen Mertens;Geoffrey Kemball-Cook.
Blood (2002)
Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome.
Frank Bienaime;Frank Bienaime;Marie-Agnes Dragon-Durey;Catherine H. Regnier;Catherine H. Regnier;Sara C. Nilsson.
Kidney International (2010)
Toward in silico structure-based ADMET prediction in drug discovery.
Gautier Moroy;Virginie Y. Martiny;Philippe Vayer;Bruno O. Villoutreix.
Drug Discovery Today (2012)
Rationalizing the chemical space of protein-protein interaction inhibitors.
Olivier Sperandio;Christelle H. Reynès;Anne-Claude Camproux;Bruno O. Villoutreix.
Drug Discovery Today (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Lund University
Lund University
Oklahoma Medical Research Foundation
Grenoble Alpes University
Leiden University Medical Center
Scripps Research Institute
Lund University
Université Paris Cité
Federal University of Toulouse Midi-Pyrénées
University of Turku
University of Pittsburgh
National Institutes of Health
Pablo de Olavide University
Royal Botanic Gardens
University of Chicago
University of Yamanashi
Medical University of South Carolina
Baylor College of Medicine
Ghent University
Science Museum
Centre national de la recherche scientifique, CNRS
University of Western Ontario
Mayo Clinic
National Institutes of Health
Yale University
University of Copenhagen